Jatenzo: How to Safely Stop Oral Testosterone Undecanoate

What Is Jatenzo and How Does It Work?

Jatenzo delivers testosterone undecanoate, a fatty-acid ester of testosterone, through an oral capsule that bypasses first-pass hepatic metabolism by absorbing through the intestinal lymphatic system rather than the portal vein. This mechanism distinguishes it from older oral androgens and from injectable or transdermal testosterone formulations.

Lymphatic absorption pathway

When swallowed with a fat-containing meal, the undecanoate ester is incorporated into chylomicrons inside enterocytes. Those chylomicrons pass directly into intestinal lymphatics (the thoracic duct), then into systemic circulation, entirely sidestepping the liver on the first pass. The FDA prescribing information confirms this mechanism explicitly. This is why Jatenzo does not carry the hepatotoxicity warnings associated with 17-alpha-alkylated oral androgens such as methyltestosterone.

Serum testosterone kinetics

Peak serum testosterone (C-max) occurs roughly 4 to 6 hours after each dose. Because the half-life of circulating testosterone undecanoate is short (approximately 3.5 hours for the parent ester in lymph), twice-daily dosing is mandatory to maintain stable serum concentrations. In the key Swerdloff et al. Trial (N=166, J Clin Endocrinol Metab 2020), 87% of men with primary or secondary hypogonadism achieved average testosterone concentrations within the normal range (300-1,000 ng/dL) after 3 months of optimized dosing. View the full trial on PubMed.

Blood pressure signal

Unlike many older androgens, Jatenzo carries an FDA black-box warning for blood pressure elevation. In the Swerdloff trial, mean systolic BP increased by 3.9 mmHg from baseline. The FDA label documents this risk and specifies monitoring at each visit. This blood-pressure concern is one reason some clinicians choose to discontinue Jatenzo even in patients who are otherwise responding well to the drug.

Why Stopping Jatenzo Requires a Plan

Exogenous testosterone, regardless of route, suppresses the hypothalamic-pituitary-gonadal axis through negative-feedback inhibition of GnRH, LH, and FSH. Research indexed at NCBI confirms that HPG suppression from exogenous androgens can persist for weeks to months after cessation. Simply stopping Jatenzo overnight leaves a man with no exogenous testosterone and an axis not yet producing adequate endogenous testosterone. The clinical result is symptomatic hypogonadism.

The washout window

Jatenzo's short serum half-life means the drug itself clears within 3 to 5 days of the last dose. Pituitary and testicular recovery takes far longer. A 2015 systematic review in JCEM (Hsieh et al., N=1,549) found that mean time to recovery of spermatogenesis after exogenous androgen cessation was 3.4 months, and complete recovery to pre-treatment sperm density took up to 6 months in some men. LH recovery typically precedes full spermatogenic recovery.

Symptom burden during the gap

Between drug clearance and HPG axis reactivation, men commonly experience:

• Fatigue and low energy (reported in more than 50% of men in androgen-deprivation trials)
• Decreased libido and erectile difficulty
• Mood changes, including irritability and low mood
• Loss of muscle mass and increased body fat, which may become measurable within 4 weeks

The Endocrine Society 2018 clinical practice guideline on male hypogonadism explicitly notes that men stopping testosterone therapy should be counseled about these transient symptoms.

Step-by-Step Jatenzo Discontinuation Protocol

The following framework synthesizes FDA labeling, the Endocrine Society 2018 guideline, and published evidence on HPG axis recovery after androgen cessation. It is not a substitute for individualized clinical judgment.

Step 1: Establish baseline labs before tapering

Order a full panel before reducing dose:

• Serum total testosterone (morning draw, 4-6 hours after dose)
• LH and FSH (to gauge degree of current suppression)
• Hematocrit and hemoglobin (polycythemia risk with TRT)
• PSA if age 40 or older
• Blood pressure measurement

The Endocrine Society guideline recommends hematocrit monitoring every 3-6 months during TRT, and the same logic applies before stopping, because hematocrit may rise transiently as the body adjusts.

Step 2: Taper the dose over 4 to 8 weeks

Jatenzo is available in three capsule strengths: 158 mg, 198 mg, and 237 mg. A practical taper schedule uses existing capsule sizes:

| Week | Dose | Schedule | |------|------|----------| | 1-2 | Drop to next lower capsule strength | Twice daily with fat-containing meal | | 3-4 | Reduce to once daily at the lower strength | With the larger meal of the day | | 5-6 | Once daily, every other day | As tolerated | | 7-8 | Stop completely |, |

Patients whose symptoms worsen significantly during this taper may need to slow the schedule. There is no published randomized trial directly testing Jatenzo-specific taper schedules; the schedule above extrapolates from HPG axis pharmacology and general TRT discontinuation practice.

Step 3: Consider HPG axis restart therapy

Men who want to restore endogenous testosterone production quickly, especially those hoping to preserve or recover fertility, may benefit from pharmacologic support during and after the taper.

Clomiphene citrate (clomid): A selective estrogen receptor modulator that blocks negative feedback at the hypothalamus and pituitary, raising LH and FSH. Off-label use at 25 to 50 mg per day is supported by multiple trials. Katz et al. (Fertil Steril 2012, N=125) showed that clomiphene raised mean serum testosterone from 247 ng/dL to 610 ng/dL over 4 months with acceptable tolerability. Starting clomiphene at the beginning of the taper is reasonable.

Human chorionic gonadotropin (hCG): Acts directly on Leydig cells (LH receptor agonist) to stimulate testosterone synthesis. Typical restart dosing is 1,500 to 3,000 IU subcutaneously three times per week for 6 to 8 weeks. A 2013 trial by Wenker et al. (J Sex Med, N=49) demonstrated that hCG monotherapy effectively raised serum T in hypogonadal men and may be used as a bridge during discontinuation.

When to avoid restart therapy: Men with primary hypogonadism (absent or non-functional testes) have no axis to restart. In these patients, stopping Jatenzo means returning to symptomatic hypogonadism unless an alternative testosterone formulation is substituted.

Step 4: Monitor labs at 4, 8, and 12 weeks post-cessation

| Time Point | Labs to Order | Target | |------------|--------------|--------| | Week 4 | Total T, LH, FSH | LH/FSH rising confirms pituitary reactivation | | Week 8 | Total T, LH, FSH, hematocrit | Total T trending toward 300 ng/dL or higher | | Week 12 | Total T, LH, FSH, semen analysis (if fertility goal) | Assess need to continue restart therapy or switch formulations |

If total testosterone remains below 300 ng/dL at 12 weeks with normal or elevated LH, the diagnosis shifts toward primary hypogonadism, and a different long-term strategy is warranted. NIH defines primary hypogonadism by the combination of low T and elevated gonadotropins.

Managing Symptoms During Discontinuation

Symptomatic hypogonadism during the washout window is predictable. Patients deserve specific, actionable guidance before they stop.

Fatigue and mood

Sleep hygiene, resistance exercise 3 to 4 days per week, and protein intake of at least 1.6 g per kilogram of body weight per day each independently support testosterone metabolism and mood. A Cochrane review (Krogh et al., 2017) found that exercise produced moderate improvements in depressive symptoms independent of hormonal status.

Libido and erectile function

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) may provide symptomatic support for erectile dysfunction during the washout window without affecting HPG axis recovery. FDA-approved labeling for tadalafil 5 mg daily supports use for erectile dysfunction regardless of testosterone status.

Polycythemia resolution

Hematocrit elevated by Jatenzo use typically falls back toward baseline within 3 months of stopping. The Endocrine Society guideline recommends holding TRT and considering phlebotomy if hematocrit exceeds 54%. After Jatenzo cessation, repeat hematocrit at 8 weeks to confirm downward trend.

Blood pressure normalization

The 3.9 mmHg mean systolic increase seen in the Swerdloff trial may partially reverse after discontinuation, though individual responses vary. AHA guidelines define hypertension as systolic BP consistently above 130 mmHg. Patients who stopped Jatenzo specifically because of BP elevation should have BP rechecked at 4 and 8 weeks after the last dose, with antihypertensive adjustments made by the prescribing physician as needed.

Special Populations and Scenarios

Men discontinuing for fertility reasons

Exogenous testosterone suppresses spermatogenesis. A landmark WHO task force study (N=670, WHO 1990) showed that testosterone-induced azoospermia takes 3 to 6 months to reverse after cessation. Men who stopped Jatenzo for fertility should be counseled that semen parameters may not normalize for 6 to 12 months. Referral to a reproductive urologist or reproductive endocrinologist at the time of discontinuation is appropriate. ASRM practice guidelines on male infertility recommend a full semen analysis no sooner than 3 months after stopping androgen therapy.

Men with cardiovascular disease

Testosterone therapy has a mixed cardiovascular evidence base. The TRAVERSE trial (N=5,246, NEJM 2023) found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events in men with hypogonadism and high CV risk, but also noted a higher rate of atrial fibrillation and pulmonary embolism in the testosterone arm. Men stopping Jatenzo because of cardiovascular concerns should have a cardiology consultation if any CV events occurred during therapy.

Older men (age 65 and above)

HPG axis recovery may be slower and less complete in older men. The Testosterone Trials (TTrials, N=790, NEJM 2016) enrolled men 65 and older and found significant physical and sexual benefits from testosterone, suggesting that older men may experience a more pronounced symptom burden when stopping. These patients warrant closer monitoring and a longer monitoring window (up to 6 months post-cessation).

Men transitioning to another TRT formulation

If the reason for stopping Jatenzo is not testosterone cessation per se but rather a switch to a different delivery system (transdermal gel, injectable testosterone cypionate, subcutaneous pellets), a taper is less critical because the new formulation maintains serum testosterone. The transition should overlap for at least one dosing cycle of the new formulation to avoid a symptomatic gap. FDA labeling for testosterone cypionate describes typical dosing intervals of 7 to 14 days for IM injection, allowing an easy overlap.

Reasons Clinicians Stop Jatenzo

Understanding why Jatenzo gets discontinued helps clinicians anticipate which discontinuation strategy to use.

Blood pressure elevation

The FDA black-box warning is the most common clinical reason for stopping Jatenzo. Per the label, Jatenzo is contraindicated in men with hypertension that is not adequately controlled. The FDA label requires blood pressure measurement before starting therapy and during each clinic visit. If systolic BP exceeds 135 mmHg on two readings, the label recommends discontinuation. The full HPG-axis taper protocol applies.

Polycythemia

Hematocrit above 54% is a standard stopping criterion across all testosterone formulations. The Endocrine Society guideline recommends stopping TRT and evaluating for secondary causes of erythrocytosis. Once hematocrit falls below 50%, some clinicians restart at a lower dose; others transition to a different formulation.

Lack of symptomatic response

Some men reach target serum T levels but do not experience meaningful symptom improvement. A meta-analysis by Isidori et al. (J Clin Endocrinol Metab 2014, N=2,034) found that testosterone's effect on fatigue and mood, though statistically significant, was modest in magnitude. Men who are non-responders can stop Jatenzo without a prolonged taper concern around symptom preservation, since the drug was not producing symptomatic benefit to begin with.

Prostate concerns

Although observational data do not establish testosterone as a cause of prostate cancer, PSA elevation above 1.4 ng/mL from baseline over 12 months is a stopping criterion per the Endocrine Society. The guideline recommends urology referral before considering any restart.

What to Expect: A Timeline After the Last Dose

| Time After Last Dose | Expected Biology | |---------------------|-----------------| | Day 3-5 | Jatenzo fully cleared from circulation | | Week 1-2 | Serum T drops; LH/FSH begin rising if secondary hypogonadism | | Week 4-6 | LH/FSH typically peak as pituitary rebounds | | Week 8-12 | Testicular Leydig cell response; serum T starts recovering | | Month 3-6 | Spermatogenesis resumes (variable; may take up to 12 months) | | Month 6+ | Full hormonal baseline typically re-established in secondary hypogonadism |

Men with secondary hypogonadism who were on Jatenzo for less than 12 months generally recover faster than those on longer courses. Hsieh et al. 2015 (JCEM) found that duration of androgen exposure was the strongest predictor of recovery time.

When to Call Your Prescriber Immediately

Patients stopping Jatenzo should seek prompt clinical contact if they experience:

• Systolic blood pressure above 160 mmHg on home monitoring
• Hematocrit check (if available) above 54% on any prior lab
• Chest pain, palpitations, or shortness of breath (possible atrial fibrillation risk, per TRAVERSE)
• Severe depression or suicidal ideation (rare but documented during androgen withdrawal)
• Signs of deep vein thrombosis: unilateral leg swelling, warmth, or pain

CDC data on venous thromboembolism show that testosterone-associated polycythemia raises VTE risk, a concern that persists briefly even after stopping until hematocrit normalizes.